Electrochemotherapy as a First Line Treatment in Recurrent Squamous Cell Carcinoma of the Oral Cavity and Oropharynx PDL-1 Negative and/or with Evident Contraindication to Immunotherapy: A Randomized Multicenter Controlled Trial.
Francesco PerriFrancesco LongoRoberta FuscoValeria D'AlessioCorrado AversaEttore PavoneMonica PontoneMaria Luisa MarcianoSalvatore VillanoPierluigi FrancoGiulia TogoGianluca Renato De FazioDaniele OrdanoFabio MaglittoGiovanni SalzanoMaria Grazia MaglioneAgostino GuidaFranco IonnaPublished in: Cancers (2021)
The phase IIb study involves the enrolment of 96 patients who meet the inclusion criteria (48 in the control arm and 48 in the treatment arm). The control arm involves the treatment of HNSCC with systemic treatment (cetuximab + platinum-based therapy + 5-fluorouracil). The treatment arm involves the ECT with bleomycin. The primary objective is to verify the objective response rate of patients in the control arm compared to the treatment arm.
Keyphrases
- squamous cell carcinoma
- randomized controlled trial
- stem cells
- end stage renal disease
- chronic kidney disease
- combination therapy
- newly diagnosed
- radiation therapy
- prognostic factors
- ejection fraction
- peritoneal dialysis
- health insurance
- replacement therapy
- locally advanced
- cell therapy
- patient reported outcomes
- drug induced
- cross sectional